Periodic Reporting for period 1 - B-BRIGHTER (Better Bioprinting by Light-sheet Lithography)
Berichtszeitraum: 2022-10-01 bis 2023-09-30
Cost effective bioink manufacture – The development of the bioink is led by CED.
Two LS Bioprinter prototypes are operational – Work is focussed at GUF and MYC to convert a laboratory-based device built on an open optical table to a more compact device with an acceptable footprint to be used in a laboratory environment. The device will be installed initially at the project partners IBEC-CERCA and TECH. The work is led by GUF, but has been supported by MYC and one of its experienced mechanical designers. A fundamental optical design that implements multiple patterning beams that would decrease the patterning time linearly with the number of beams. The multi-beam implementation will not be used in the two bioprinters that will be built during the project.
LS Bioprinter and bioinks produce bioprinted tissues – The main work of printing the tissue types that have been identified for the B-BRIGHTER project, namely gut, skin and cornea, is being prepared at present while waiting for the delivery of the two bioprinters during 2024. Preliminary work is being undertaken by IBEC-CERCA and TECH with the existing printing device at GUF to facilitate the coming work with the new bioprinters.
Bioprinting data valid for the business case – A significant amount of work has been performed to shape the business case for a valid business offering. This includes interacting with stakeholders, utilising business case development strategies for deep tech innovations, and carrying out workshops within the project. Further work will be carried out to better understand existing and future users of bioprinters will require with respect to bioprinter specifications, such as resolution, printing speed, utilisation time, et cetera.
Work continues in the project to produce new bioprinters, as well as developing a viable business case. Work with the business case of the technology requires further development of the relevant use cases, interactions with existing and possible future users. Support concerning regulatory aspects is being identified, as is mentoring concerning how to access funding opportunities for a proposed spin-off.